and clinical T1/T2 prostate cancer. All patients were treated with primary dose-escalated RT (75.6 Gy or RT with a brachytherapy boost). Overall survival was analyzed with propensity score adjustment and Cox multivariate modeling. RESULTS: The study included 18,598 patients. The use of ADT decreased from 43.5% in 2004 to 39.5% in 2007. The propensity score-adjusted survival analysis demonstrated similar 8-year overall survival for men treated with dose-escalated RT and ADT and men treated with RT alone (77.7% vs 78.4%). ADT was not associated with improved survival in any age or comorbidity subgroup. In a sensitivity analysis using Cox multivariate modeling, the receipt of ADT was not associated with overall survival (hazard ratio, 0.99; 95% confidence interval, 0.91-1.07; P 5 .768). CONCLUSIONS: Adding ADT to modern dose-escalated RT was not associated with improved survival for patients with favorable intermediate-risk prostate cancer. The applicability of the survival benefit seen in older trials to modern patients is unclear.
INTRODUCTION
Randomized trials conducted in the 1980s and 1990s demonstrated that the addition of androgen-deprivation therapy (ADT) to radiotherapy (RT) improves overall survival for patients with aggressive prostate cancer. [1] [2] [3] Most of the published trials involved patients with high-risk or locally advanced disease, [1] [2] [3] and these results firmly established the combination of RT with ADT as a standard of care for these patients. 4 On the other hand, the role of concurrent ADT with RT for patients with intermediate-risk prostate cancer is controversial. Radiation Therapy Oncology Group (RTOG) 94-08 was a randomized trial that included 1979 patients with early prostate cancer; patients were treated either with RT to 66.6 Gy or with RT with 4 months of ADT. Among the intermediate-risk patients, the 10-year overall survival rate was 54% with RT and 61% with RT and ADT. 5 Whether this modest absolute survival benefit applies to modern intermediate-risk patients is unclear. First, standard radiation doses are now much higher (75.6 Gy or higher) than those used in the RTOG trial (66.6 Gy), and this likely mitigates some of the observed benefit from ADT. Furthermore, intermediate risk encompasses a wide range of patients with different degrees of disease aggressiveness and prognoses; it is now commonly accepted that a subset of patients with favorable intermediate-risk disease according to clinical characteristics have more favorable outcomes than the patients studied overall in the randomized trials. 6 It is controversial whether these favorable intermediate-risk patients benefit from the addition of ADT to modern dose-escalated RT; this debate is further fueled by the increasing awareness of potential long-term morbidity associated with ADT.
Demonstrating the current clinical uncertainty, the National Comprehensive Cancer Network (NCCN) guidelines recommend dose-escalated external-beam RT with or without short-term ADT (for 4-6 months) as treatment options for intermediate-risk prostate cancer. 4 To provide evidence to inform this debate, the goal of this current study was to examine whether the addition of ADT to modern dose-escalated RT improves overall survival for patients with favorable intermediate-risk prostate cancer. We used data from the National Cancer Data Base (NCDB), a large nationwide cancer registry that includes approximately 70% of cancer patients from across the United States. 8 
MATERIALS AND METHODS

Data Source
The NCDB is jointly maintained by the . This was similar to previously published definitions. 6, 9, 10 Included patients were all treated with dose-escalated RT, which was defined as externalbeam RT to a dose of 75.6 Gy per NCCN guidelines, 4 or a combination of external-beam RT with a brachytherapy boost. No patients underwent prostatectomy before RT. ADT had to have been initiated before or on the first date of RT treatment to be considered concurrent. An inclusion schema is shown in Table 1 . The final analytic cohort consisted of 18,598 patients.
Statistical Analysis
The change over time in the proportion of patients who received ADT was reported, and statistical significance was evaluated with the Cochran-Armitage test for trend.
Baseline patient characteristics were summarized by treatment modality (RT or RT with ADT). Overall survival was evaluated with Kaplan-Meier analysis, and unadjusted hazard ratios were reported. Propensity scores were computed with logistic regression models to account for potentially clinically relevant factors such as patient age, race, regional income and education, insurance status, year of diagnosis, type of treatment facility, geographic region, comorbidity (Charlson/Deyo score), PSA group (10 vs 10.1-20 ng/mL), clinical T stage, and Gleason score. The propensity score model also included interaction terms for age with comorbidity, PSA, T stage, and Gleason score because age is a strong determinant of not only treatment but also the survival outcome.
Our primary analysis was a propensity score weightadjusted overall survival comparison of patients who received RT alone and patients who received RT with 
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ADT. Inverse probability weight-adjusted survival curves were created with the method described by Cole and Hernan. 11 The statistical significance of differences in survival was assessed with confidence intervals (CIs) for 5-, 7-, and 8-year survival estimates. We performed additional comparisons by patient subgroups based on age and Abbreviations: ADT, androgen-deprivation therapy; NOS, not otherwise specified; PSA, prostate-specific antigen; RT, radiotherapy. a Propensity score-weighted patient numbers are rounded to the nearest integer.
comorbidity score to discern whether an overall survival benefit could be seen in different patient groups.
For a sensitivity analysis, we constructed multivariate Cox proportional hazards models to examine whether the addition of ADT was significantly associated with overall survival. Hazard ratio estimates were adjusted for the same potentially relevant factors used in the computation of propensity scores. For all the statistical analyses, 2-sided P values were calculated, with a level < .05 considered statistically significant. All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
Unadjusted and propensity score-adjusted patient cohort characteristics are summarized in Table 2 . Before the propensity score adjustment, differences were observed between the 2 comparison groups in insurance status, treatment facilities, geographic regions, and Gleason scores. After the adjustment, these differences were eliminated. In the adjusted model, the median follow-up for patients treated with RT alone was 75.0 months (interquartile range, 63.7-89.3 months), and for patients treated with RT and ADT, the median follow-up was 75.6 months (interquartile range, 63.6-89.0 months).
The concurrent use of ADT with RT across the United States decreased over time (P < . In the unadjusted patient cohort, the receipt of ADT with RT was associated with a higher risk of death (hazard ratio, 1.09; 95% CI, 1.01-1.17; P 5 .029).
Propensity score-adjusted overall survival results for the entire cohort are shown in Figure 1 , with survival curves superimposable for RT and RT/ADT patient groups. The 5-year overall survival rate was 89.6% (95% CI, 89.0%-90.3%) for RT alone and 90.1% (95% CI, 89.4%-90.8%) for RT with ADT; the 8-year results were 78.4% for RT (95% CI, 77.2%-79.6%) and 77.7% for RT with ADT (95% CI, 76.3%-79.2%). Adjusted survival curves for patient subgroups by age and comorbidity are shown in Figures 2 and 3 . In no subgroup was there a significant difference in overall survival between patients treated with RT alone and patients treated with RT and ADT. That is, overall and stratified inverse probabilityweighted Cox regression analyses did not show any significant difference in survival between patients who received RT alone and those who received RT with ADT (Table 3) .
A Cox proportional hazards model revealed a consistent result (Table 4 ). There was no significant association between receiving ADT and overall survival (hazard ratio, 0.99; 95% CI, 0.91-1.07; P 5 .768). On the other hand, a higher comorbidity score, age, and stage were all associated with increased mortality. For a sensitivity analysis, an additional Cox multivariate model was constructed, to which "brachytherapy boost" was added as a covariate; this did not change the finding that ADT was not associated with improved survival (hazard ratio for ADT vs no ADT, 0.98; P 5 .596).
DISCUSSION
This study of 18,598 patients from a large nationwide cancer registry demonstrated no overall survival benefit from the addition of ADT to dose-escalated RT among modern patients with favorable intermediate-risk prostate cancer. This study directly addresses a current area of controversy to inform clinical decisions, and it provides evidence from the largest study to date.
Whether modern patients receiving dose-escalated RT benefit from concurrent ADT is unknown. This is reflected in published guidelines, 4 which recommend either dose-escalated RT alone or dose-escalated RT with concurrent short-term ADT for intermediate-risk prostate cancer. Furthermore, a currently enrolling randomized trial (RTOG 0815) is directly comparing dose-escalated RT and ADT with dose-escalated RT without ADT (NCT00936390), and this signifies equipoise and the importance of this clinical question. However, overall survival results from this trial may not be available to inform clinical decision making for another decade. In the meantime, data are needed to inform clinical decisions, but Original Article almost no published studies have directly examined the question asked by the current study.
The debate about ADT centers around several issues. First, prior randomized trials using lower dose RT demonstrated relatively modest survival benefits from concurrent ADT. 1, 5 Modern dose-escalated RT is likely to make this overall survival benefit even smaller or possibly completely eliminate the benefit from ADT. Second, the harms of ADT have been increasingly described over the past few years and include cardiovascular morbidity, fatigue, sexual dysfunction, and bone loss 12 ; with this increasing awareness of the potential tradeoffs of ADT, any potential survival benefit has to be balanced against these morbidities. Three, there is an increasing acknowledgment of the heterogeneity of intermediate-risk prostate cancer; with favorable intermediate-risk behaving more like low-risk disease and therefore identifying a group of patients least likely to derive benefit from adding ADT to dose-escalated RT. Indeed, our finding that less than half of these patients received ADT (with ADT use decreasing over time) demonstrates the manifestation of these considerations in clinical practice across the United States.
A prior randomized trial suggested that the overall survival benefit conferred by ADT (added to conventional/lower doses of RT) in intermediate-risk patients may be seen primarily in those with minimal comorbidity; patients with moderate to severe comorbidities may not derive a survival benefit from the addition of ADT to RT. 1 A recent long-term update of this study no longer found a significant overall survival benefit from ADT. 13 The current study evaluated this question directly by stratifying patients according to their Charlson/Deyo comorbidity scores in a subgroup analysis. Importantly, our results showed that among patients with favorable intermediate-risk prostate cancer, even those patients who had minimal comorbidity did not appear to benefit from the addition of ADT to dose-escalated RT. However, it is notable that the Charlson-Deyo score does not specifically capture functional status, cardiac risk factors, or life expectancy, which are important considerations in this patient population. Our study extends findings from the prior clinical trial and fills a current knowledge gap: even in healthy patients, avoiding ADT for favorable intermediate-risk disease treated with modern doseescalated RT could be a reasonable option. This option may be further strengthened when one weighs the morbidities that are associated with ADT 10 against a lack of a significant benefit in this patient population.
Our search of the literature found several studies examining the potential benefit of ADT in the setting of dose-escalated RT specifically for patients with favorable intermediate-risk prostate cancer. In the singleinstitution study by Bian et al, 14 302 patients with favorable intermediate-risk prostate cancer were retrospectively analyzed, and no improvement was seen in failure-free survival. These results are consistent with those from our study, but the prior study was smaller and had a less representative patient population, and overall survival was not examined. Additional retrospective studies have similarly demonstrated that the addition of ADT to dose-escalated RT does not improve prostate cancer outcomes. 15, 16 There are multiple strengths and limitations of our study. One limitation is the retrospective design and potential for confounding. We tried to minimize this by performing propensity score-weighted analyses and also constructing Cox multivariate models for a sensitivity analysis. For example, we included the year of diagnosis in multivariate models to account for changes in treatment techniques over time and differences in follow-up for the patient cohorts. The consistency of our findings through multiple analytic methodologies strengthens the validity of our conclusion that ADT does not improve survival for patients with favorable intermediate-risk prostate cancer in the setting of modern dose-escalated RT. On the other hand, no randomized trial data are currently available to inform this specific (clinically relevant and controversial) question. It is possible that with longer follow-up, a difference in survival might be observed between patients who receive ADT and patients who do not receive ADT, Original Article although in the current study, there was no evidence of a survival difference even in later years of follow-up.
A limitation of the NCDB is the lack of some specific data elements that would have been useful to this study. This includes a lack of information on recurrence and cancer-specific survival, which are clinically relevant endpoints. However, it should be noted that assessing biochemical recurrence in a setting of ADT (for 1 of the 2 comparison arms) is difficult because of the direct effect of testosterone suppression on PSA measures, which can linger for years after the cessation of ADT. 17 The NCDB does not contain information pertaining to toxicity from treatment, which is not considered in the current analysis. We feel that an overall survival comparison, which was performed in this study, is perhaps the most informative for patients and their physicians. Another data element that would have been useful is the percentage of biopsy cores containing cancer; this is prognostic for disease-free survival. 18 However, we are not aware of any large population-based data set that contains this information for patients treated during the years of this study. The NCDB also lacks information regarding the type of ADT used and the duration of ADT. The duration of ADT is an important consideration when one is evaluating the risks and benefits of adding ADT to RT. Several randomized trials have compared short-term ADT with long-term ADT with RT for prostate cancer. [19] [20] [21] However, these trials included a mixture of patients with locally advanced, high-risk, and intermediate-risk disease, so it is unclear whether the benefit of long-term ADT over shortterm ADT applies to the subset of patients with favorable intermediate-risk prostate cancer treated with modern dose-escalated RT.
An important strength of this study is the large sample size of NCDB patients. The NCDB includes approximately 70% of incident cancers in the United States, with the majority of patients treated in the community. Thus, the current study informs patients and physicians about the effectiveness of ADT for favorable intermediate-risk patients, whereas future reporting of clinical trial data will show the efficacy of ADT in select patients treated in controlled settings. Another strength related to large sample size was the ability to perform subgroup analyses by age and comorbidity score; this more comprehensively addresses the question of the potential benefit of ADT in clinically relevant patient populations. Subgroup comparisons can be more difficult in clinical trials because of the limited sample size and power of subgroups.
In conclusion, using a broad United States-based cohort, this study showed that among patients with favorable intermediate-risk prostate cancer, the addition of ADT to modern dose-escalated RT was not associated with improved overall survival for any patient subgroup based on age or comorbidity score. This study is clinically relevant and directly informs a current area of significant controversy. Until results from randomized trials are available, this study represents the largest to date for informing patients and physicians on the effectiveness of ADT in this patient population.
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